Updated 10 August 2020 This document presents an essential medicines list (EML) to manage patients in intensive care units (ICUs) with suspected or confirmed COVID-19 diagnosis, which includes active ingredients with dosage form and concentration, and are preferably in the WHO Model Lists of Essential Medicines 2019; based on clinical presentations and symptoms identified and prioritized in World Health Organization (WHO) and Surviving Sepsis Campaign (SSC) guidelines and the evidence presented in these guidelines

24 marzo 2020 El objetivo de este documento es elaborar una lista de medicamentos esenciales para manejar los pacientes en unidades de cuidados intensivos con sospecha o diagnóstico confirmado de COVID -19. Incluye principios activos con su forma farmacéutica y concentración —preferentemente entre los recogidos en la Lista Modelo de Medicamentos Esenciales de la OMS (2019)—, con base en los cuadros clínicos y los síntomas identificados y priorizados en las guías de la OMS y de Surviving Sepsis Campaign y en las evidencias presentadas en dichas guías

Este documento presenta una actualización de las recomendaciones interinas de la Organización Panamericana de la Salud para la gestión de los casos de COVID-19 en los servicios de salud. La lista de dispositivos médicos prioritarios en el contexto de la COVID-19 proporciona normas mínimas, descripciones técnicas y especificaciones para el manejo de pacientes con sospecha o confirmación de infección por coronavirus en los distintos niveles del entramado asistencial y puntualmente para todas las etapas de atención

Elaborar uma lista de medicamentos essenciais (LME) para tratamento de pacientes nas Unidades de Terapia Intensiva com suspeita ou diagnóstico confirmado da COVID-19, incluindo os princípios ativos com sua forma farmacêutica e concentração e que, de preferência, estejam na Lista Modelo de Medicamentos Essenciais da OMS 2019; com base nos quadros clínicos e sintomas identificados e priorizados nas Diretrizes da Organização Mundial da Saúde (OMS) e da Campanha de Sobrevivência à Sepse (SSC - sigla em inglês para Surviving Sepsis Campaign)1, 3, e nas evidências apresentadas nas referidas diretrizes

Este documento é uma atualização das Orientações provisórias da OPAS para o gerenciamento de casos de COVID-19 nos serviços de saúde. A lista de dispositivos médicos prioritários no contexto do vírus COVID-19 fornece descrições técnicas e especificações para o manejo de pacientes com suspeita e/ou confirmação de infecção por COVID-19 nos diferentes níveis de complexidade do tratamento e para as fases de atendimento. Esclarecemos que a lista incluída neste documento deve ser adaptada ao contexto de cada país da região, de acordo com as necessidades e capacidades de seus sistemas de saúde

Using the WHO model list of essential medicines to update a national essential medicines list Since 1977, WHO has been working with countries to design the package of essential medicines as an integral component of treatment within the continuum of care, developing and disseminating the Model List of Essential Medicines (Model List). WHO is committed to supporting Member States in sharing best practices in selecting essential medicines, and in developing processes for the selection of medicines for national essential medicines lists (national EMLs, or NEMLs) consistent with the evidence-based methods used for updating the WHO Model List

The Kenya Essential Medicines List 2019 is an indispensable guide to the medicines recommended for the management of common conditions in Kenya. It is primarily directed at health care providers and medicines supply managers in the public and non-public health sectors. It should be used together with the current versions of updated national clinical guidelines for those conditions for which such guidelines exis

WHO’s Essential Medicines List and List of Essential Diagnostics are core guidance documents that help countries prioritize critical health products that should be widely available and affordable throughout health systems. The updated Essential Medicines List adds 23 medicines for children

Cancer treatments: While several new cancer treatments have been marketed in recent years, only a few deliver sufficient therapeutic benefits to be considered essential. The 12 medicines WHO added to the new Medicines List for five cancer therapies are regarded as the best in terms of survival rates to treat melanoma, lung, prostate, multiple myeloma and leukemias cancers. For example, two recently developed immunotherapies (nivolumab and pembrolizumab) have delivered up to 50% survival rates for advanced melanoma, a cancer that until recently was incurable. Antibiotics: The Essential Medicines Committee strengthened advice on antibiotic use by updating the AWARE categories, which indicate which antibiotics to use for the most common and serious infections to achieve better treatment outcomes and reduce the risk of antimicrobial resistance. The committee recommended that three new antibiotics for the treatment of multi-drug resistant infections be added as essential. Other updates to the medicines list include: New oral anticoagulants to prevent stroke as an alternative to warfarin for atrial fibrillation and treatment of deep vein thrombosis. These are particularly advantageous for low-income countries as, unlike warfarin, they do not require regular monitoring; Biologics and their respective biosimilars for chronic inflammatory conditions such as rheumatoid arthritis and inflammatory bowel diseases; Heat-stable carbetocin for the prevention of postpartum haemorrhage. This new formulation has similar effects to oxytocin, the current standard therapy, but offers advantages for tropical countries as it does not require refrigeratio